Transfusion-sparing hemostatic agents

Current Opinion in Hematology

Volumn 9, Issue 6, 2002, Pages 544-550

  Chiu, Jason ^a   Ketchum, Lloyd H ^a   Reid, Thomas J ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; APROTININ; CONJUGATED ESTROGEN; CYPLEX; DESMOPRESSIN ACETATE; FIBRIN GLUE; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 11; RECOMBINANT THROMBOPOIETIN; SERINE PROTEINASE INHIBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VITAMIN K GROUP; COAGULATING AGENT; HEMOPOIETIC GROWTH FACTOR;

ABDOMINAL PAIN; ANTICOAGULATION; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; COMPETITIVE INHIBITION; CONGESTIVE HEART FAILURE; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DYSPNEA; FIBRINOLYSIS; FLUID RETENTION; HEMOSTASIS; HUMAN; HYPOTENSION; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; TACHYPHYLAXIS; THROMBOCYTOPENIA; THROMBUS; TREATMENT INDICATION; VOMITING; BANDAGE; DRUG EFFECT;

ANTIFIBRINOLYTIC AGENTS; BANDAGES; BLOOD TRANSFUSION; COAGULANTS; HEMATOPOIETIC CELL GROWTH FACTORS; HEMORRHAGE; HEMOSTASIS; HUMANS;

EID: 0036838269     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200211000-00014     Document Type: Review

References (122)

1. Mannucci PM, Canciani MT, Rota L, et al.: Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with hemophilia A and von Willebrand's disease. Br J Haematol 1981, 47: 283-293.
2. Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997, 90: 2515-2521.
3. Engelfriet CP, Reesink HW, Mannucci PM, et al.: The optimal treatment for hemophiliacs who have developed factor VIII or -IX antibodies. Vox Sang 2000, 78: 256-261.
4. Ingerslev J: Hemophilia. Strategies for the treatment of inhibitor patients. Hematologica 2000, 85(10 Suppl): 15-20.
5. Lusher JM: Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials. Hematologica 2000, 85(10 Suppl): 2-5; discussion 5-6.
6. Lusher JM: Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000, 26: 179-188.
7. Shobeiri SA, West EC, Kahn MJ, et al.: Postpartum acquired hemophilia (factor VIII inhibitors): a case report and review of the literature. Obstet Gynecol Surv 2000, 55: 729-737.
8. Gribble J and Garvey MB: Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII. Hemophilia 2000, 6: 482-485.
9. Ingerslev J: Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000, 26: 425-432.
10. Shord SS and Lindley CM: Coagulation products and their uses. Am J Health Syst Pharm 2000, 57: 1403-1417; quiz 1418-1420.
11. Holmberg L, Nilsson IM, Borge L, et al.: Platelet aggregation induced by 1 -desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med 1983, 309: 816-821.
12. Mannucci PM, Bettega D, and Cattaneo M: Patterns of development of tachyphylaxis in patients with hemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992, 82: 87-93.
13. Mannucci PM and Federici AB: Management of inherited von Willebrand disease. Best Pract Res Clin Haematol 2001, 14: 455-462.
14. Michiels JJ, Budde U, van der Planken M, et al.: Acquired von Willebrand syndromes: clinical features, etiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001, 14: 401-436.
15. Wright D, Poller L, Thomson JM, et al.: The effect of hormone replacement therapy of the age-related rise of factor VIIc, and its activity state. Thromb Res 1997, 85: 455-464.
16. Quehenberger P, Loner U, Kapiotis S, et al.: Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 1996, 76: 729-734.
17. Lindley CM, Sawyer WT, Macik BG, et al.: Pharmacokinetics and pharmaco-dynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994, 55: 638-648.
18. Hedner U: Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol 2001, 38(4 Suppl 12): 43-47.
19. Kenet G, Walden R, Eldad A, et al.: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999, 354: 1879.
20. Martinowitz U, Kenet G, Segal E, et al.: Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001, 51: 431 -438; discussion 438-439.
21. Furie B, Bouchard BA, and Furie BC: Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 1999, 93: 1798-1808.
22. Ansell J, Hirsh J, Dalen J, et al.: Managing oral anticoagulant therapy. Chest 2001, 119(1 Suppl): 22S-38S.
23. Ellenhorn MJ and Barceloux DG: Anticoagulants, Antifibrinolytic Agents and Thrombolytic Agents. In Ellenhorn's medical toxicology: diagnosis and treatment of human poisoning. Baltimore: Williams & Wilkins; 1997: 452-463.
24. Jelkmann W: Erythropoietin: structure, control of production, and function. Physiol Rev 1992, 72: 449-489.
25. Pirisi M, Fabris C, Soardo G, et al.: Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol 1994, 21: 376-380.
26. Stohlawetz PJ, Dzirlo L, Hergovich N, et al.: Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000, 95: 2983-2989.
27. Flaharty KK: Clinical pharmacology of recombinant human erythropoietin (r-HuEPO). Pharmacotherapy 1990, 10(2 (Pt 2)): 9S-14S.
28. Vadhan-Raj S, Murray U, Bueso-Ramos C, et al.: Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997, 126: 673-681.
29. Basser RL, Rasko JE, Clarke K, et al.: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG·rHuMGDF) in patients with advanced cancer. Lancet 1996, 348: 1279-1281.
30. Basser RL, Underhill C, Davis I, et al.: Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 2000, 18: 2852-2861.
31. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al.: Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000, 132: 364-368.
32. Archimbaud E, Ottmann OG, Yin JA, et al.: A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG·rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999, 94: 3694-3701.
33. Schiffer CA, Miller K, Larson RA, et al.: A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000, 95: 2530-2535.
34. Bolwell B, Vredenburgh J, Overmoyer B, et al.: Safety and biologic effect of pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients following autologous peripheral blood progenitor cell transplantation. Blood 1997, 90: 171 a.
35. Komatsu N, Okamoto T, Yoshida T: Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHUMGDF) increased platelet counts in patients with aplastic anemia and myelodysplastic syndromes. Blood 2000, 96: 296a.
36. Dan K, Nomura S, Hotta T, et al.: Biological effect of pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with idiopathic thrombocytopenia purpura. Blood 2001, 98: 299a.
37. Harker LA, Carter RA, Marzec UM, et al.: Correction of thrombocytopenia and ineffective platelet production in patients with human immunodefieciency virus (HIV) by PEG-rHuMGDF therapy. Blood 1998, 92: 707a.
38. Kuter DJ: Whatever happened to thrombopoietin? Transfusion 2002, 42: 279-283.
39. Begley CG and Basser RL: Biologic and structural differences of thrombopoietic growth factors. Semin Hematol 2000, 37(2 Suppl 4): 19-27.
40. Du X and Williams DA: Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997, 89: 3897-3908.
41. Goldman SJ: Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 1995, 13: 462-471.
42. Kaye JA: The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor). Stem Cells 1996, 14 Suppl 1: 256-260.
43. Kaye JA: Clinical development of recombinant human interleukin-11 to treat chemotherapy-induced thrombocytopenia. Curr Opin Hematol 1996, 3: 209-215.
44. Tepler I, Elias L, Smith JW 2nd, et al.: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996, 87: 3607-3614.
45. Turner KJ, Goldman SJ, Kaye JA, et al.: Thrombopoiesis and thrombopoietin: the significance of 'non-Tpo' cytokines. Blood 1996, 87: 3065-3067.
46. Kaye JA: FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells 1998, 16 Suppl 2: 207-223.
47. Owens MR: The role of platelet microparticles in hemostasis. Transfus Med Rev 1994, 8: 37-44.
48. Lee DH and Blajchman MA: Novel treatment modalities: new platelet preparations and substitutes. Br J Haematol 2001, 114: 496-505.
49. Scigliano E, Enright H, Telen M, et al.: Infusible platelet membrane (IPM) for control of bleeding in thrombocytopenic patients. Blood 1997, 90: 267a.
50. Alving BM, Reid TJ, Fratantoni JC, et al.: Frozen platelets and platelet substitutes in transfusion medicine. Transfusion 1997, 37: 866-876.
51. Gao DY, Neff K, Xiao HY, et al.: Development of optimal techniques for cryopreservation of human platelets. I. Platelet activation during cold storage (at 22 and 8 degrees C) and cryopreservation. Cryobiology 1999, 38: 225-235.
52. Bode AP: Preclinical testing of lyophilized platelets as a product for transfusion medicine. Transfus Sci 1995, 16: 183-185.
53. Read MS, Reddick RL, Bode AP, et al.: Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion. Proc Natl Acad Sci U S A 1995, 92: 397-401.
54. Bode AP, Read MS, and Reddick RL: Activation and adherence of lyophilized human platelets on canine vessel strips in the Baumgartner perfusion chamber. J Lab Clin Med 1999, 133: 200-211.
55. Verstraete M: Clinical application of inhibitors of fibrinolysis. Drugs 1985, 29: 236-261.
56. Dunn CJ and Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999, 57: 1005-1032.
57. Hiippala ST, Strid U, Wennerstrand MI, et al.: Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg 1997, 84: 839-844.
58. Katsaros D, Petricevic M, Snow NJ, et al.: Tranexamic acid reduces postby pass blood use: a double-blinded, prospective, randomized study of 210 patients. Ann Thorac Surg 1996, 61: 1131-1135.
59. Vander Salm TJ, Kaur S, Lancey RA, et al.: Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1996, 112: 1098-1107.
60. Boylan JF, Klinck JR, Sandler AN, et al.: Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996, 85: 1043-1048; discussion 1030A-1031A.
61. Bartholomew JR, Salgia R, and Bell WR: Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med 1989, 149: 1959-1961.
62. Gardner FH and Helmer RE 3rd, Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 1980, 243: 35-37.
63. Bonnar J and Sheppard BL: Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996, 313: 579-582.
64. Henry DA and O'Connell DL: Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal hemorrhage. BMJ 1989, 298: 1142-1146.
65. Sindet-Pedersen S: Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study. J Clin Pharmacol 1987, 27: 1005-1008.
66. Sindet-Pedersen S, Ramstrom G, Bernvil S, et al.: Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989, 320: 840-843.
67. Okamoto S, Sato S, Takada Y, et al.: An active stereoisomer (transform) of AMCHA and its antifibrinolytic (antiplasmic) action in vitro and in vivo. Keio J Med 1964, 13: 177.
68. Mannucci PM: Hemostatic drugs. N Engl J Med 1998, 339: 245-253.
69. Butterworth J, James RL, Lin Y, et al.: Pharmacokinetics of epsilonaminocaproic acid in patients undergoing aortocoronary bypass surgery. Anesthesiology 1999, 90: 1624-1635.
70. Hedner U, Hirsh J, and Marder VJ: Therapy with antifibrinolytic agents. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Edited by Colman RW, Hirsh J, Marder VJ, et al. Philadelphia: Lippincott Williams & Wilkins: 2001; 795-813.
71. Kane MJ, Silverman LR, Rand JH, et al.: Myonecrosis as a complication of the use of epsilon amino-caproic acid: a case report and review of the literature. Am J Med 1988, 85: 861-863.
72. Seymour BD and Rubinger M: Rhabdomyolysis induced by epsilonaminocaproic acid. Ann Pharmacother 1997, 31: 56-58.
73. Lindoff C, Rybo G, and Astedt B: Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993, 70: 238-240.
74. Stefanini M, English HA, and Taylor AE: Safe and effective, prolonged administration of epsilon aminocaproic acid in bleeding from the urinary tract. J Urol 1990, 143: 559-561.
75. Williams EC: Plasma alpha 2-antiplasmin activity. Role in the evaluation and management of fibrinolytic states and other bleeding disorders. Arch Intern Med 1989, 149: 1769-1772.
76. Adams HP Jr, Kassell NF, Torner JC, et al.: Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology 1987, 37: 1586-1591.
77. Longstaff C: Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis 1994, 5: 537-542.
78. Fritz H and W, G: Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983, 33: 479-494.
79. D'Errico CC, Shayevitz JR, Martindale SJ, et al.: The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 1996, 83: 1193-1199.
80. Royston D, Bidstrup BP, Taylor KM, et al.: Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987, 2: 1289-1291.
81. Prendergast TW, Furukawa S, Beyer AJ 3rd, et al.: Defining the role of aprotinin in heart transplantation. Ann Thorac Surg 1996, 62: 670-674.
82. Wildevuur CR, Eijsman L, Roozendaal KJ, et al.: Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989, 3: 533-537; discussion 537-538.
83. Royston D BB, Taylor KM, Sapsford RN: Aprotinin (Trasylol) reduces bleeding after open heart surgery in patients taking aspirin and those with renal failure. Anesthesiology 1989, 71 (Suppl:A6): abstract.
84. Royston D: Preventing the inflammatory response to open-heart surgery: the role of aprotinin and other protease inhibitors. Int J Cardiol 1996, 53 Suppl: S11-37.
85. Wachtfogel YT, Kucich U, Hack CE, et al.: Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993, 106: 1-9; discussion 9-10.
86. Mallett SV, Cox D, Burroughs AK, et al.: Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet 1990, 336: 886-887.
87. Neuhaus P, Bechstein WO, Lefebre B, et al.: Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1989, 2: 924-925.
88. Dietrich W, Spath P, Ebell A, et al.: Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997, 113: 194-201.
89. Diefenbach C, Abel M, Limpers B, et al.: Fatal anaphylactic shock after aprotinin reexposure in cardiac surgery. Anesth Analg 1995, 80: 830-831.
90. Hayes A, Murphy DB, and McCarroll M: The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth 1996, 8: 357-360.
91. Lass M, Welz A, Kochs M, et al.: Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy. Eur J Cardiothorac Surg 1995, 9: 206-210.
92. Bennett-Guerrero E, Sorohan JG, Gurevich ML, et al.: Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. Anesthesiology 1997, 87: 1373-1380.
93. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al.: Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a metaanalysis. Circulation 1999, 99: 81-89.
94. Murkin JM: Con: tranexamic acid is not better than aprotinin in decreasing bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 1994, 8: 474-476.
95. Dietrich CP, Shinjo SK, Moraes FA, et al.: Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine. Semin Thromb Hemost 1999, 25 Suppl 3: 43-50.
96. Byun Y, Singh VK, and Yang VC: Low molecular weight protamine: a potential nontoxic heparin antagonist. Thromb Res 1999, 94: 53-61.
97. Carr JA and Silverman N: The heparin-protamine interaction. A review. J Cardiovasc Surg (Torino) 1999, 40: 659-666.
98. Despotis GJ, Gravlee G, Filos K, et al.: Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999, 91: 1122-1151.
99. Petratos PB, Rucker GB, Soslow RA, et al.: Evaluation of octylcyanoacrylate for wound repair of clinical circumcision and human skin incisional healing in a nude rat model. J Urol 2002, 167(2 Pt 1): 677-679.
100. Teoh KH, Young E, Bradley CA, et al.: Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Circulation 1993, 88(5 Pt 2): 11420-425.
101. Milas BL, Jobes DR, and Gorman RC: Management of bleeding and coagulopathy after heart surgery. Semin Thorac Cardiovasc Surg 2000, 12: 326-336.
102. Porsche R and Brenner ZR: Allergy to protamine sulfate. Heart Lung 1999, 28: 418-428.
103. Ravi R and Frost EA: Cardiac surgery in patients with protamine allergy. Heart Dis 1999, 1: 289-294.
104. Shekarriz B and Stoller ML: The use of fibrin sealant in urology. J Urol 2002, 167: 1218-1225.
105. Radosevich M, Goubran HI, and Burnouf T: Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 1997, 72: 133-143.
106. Martinowitz U and Schulman S: Fibrin sealant in surgery of patients with a hemorrhagic diathesis. Thromb Haemost 1995, 74: 486-492.
107. Rakocz M, Lavie G, and Martinowitz U: Glanzmann's thrombasthenia: the use of autologous fibrin glue in tooth extractions. ASDC J Dent Child 1995, 62: 129-131.
108. Yamamoto LG: Preventing adverse events and outcomes encountered using dermabond. Am J Emerg Med 2000, 18: 511-515.
109. Galajda Z, Fulop T, and Peterffy A: Subacute left ventricular rupture complicated by free wall rupture: repair with a TachoComb sheet and Tissucol glue. J Thorac Cardiovasc Surg 2002, 123: 1014-1015; discussion 1015-1016.
110. Kaczmarczyk R, Markiewicz P, and Trojanowski T: The application and evaluation of TachoComb in repair of lacerations of dural sac [in Polish]. Neurol Neurochir Pol 2001, 35 Supp] 5: 64-69.
111. Akilov Kh A, Deviatov AV, Ibadov RA, et al.: Use of the glue composition TachoComb in forming the portosystemic anastomosis [in Russian]. Vestn Khir Im II Grek 2001, 160: 87-89.
112. Skipenko OG, Shatverian GA, Movchun AA, et al.: Application of wound coat 'Tachocomb' in surgical interventions on liver and pancreas [in Russian]. Khirurgiia (Mosk) 1998, 1: 11-14.
113. Martis G, Miko I, Szendroi T, et al.: Results with collagen fleece coated with fibrin glue (TachoComb). A macroscopical and histologic experimental study. Acta Chir Hung 1997, 36: 221-222.
114. Agus GB, Bono AV, Mira E, et al.: Hemostatic efficacy and safety of TachoComb in surgery. Ready to use and rapid hemostatic agent. Int Surg 1996, 81: 316-319.
115. Scheyer M and Zimmermann G: Tachocomb used in endoscopic surgery. Surg Endosc 1996, 10: 501-503.
116. Vykouril L and Bedrna J: Conclusions from the clinical trials of TachoComb, a hemostatic [in Czech] . Rozhl Chir 1996, 75: 216-218.
117. Lorenz D and Scheele J: The use of collagen fleece (Tachocomb) in pancreatic surgery [in German]. Z Exp Chir Transplant Kunstliche Organe 1990, 23: 93-94.
118. Hollaus P and Pridun N: The use of Tachocomb in thoracic surgery. J Cardiovasc Surg (Torino) 1994, 35(6 Suppl 1): 169-170.
119. Cornum RL, Morey AF, Harris R, et al.: Does the absorbable fibrin adhesive bandage facilitate partial nephrectomy? J Urol 2000, 164(3 Pt 1): 864-867.
120. Anema JG, Morey AF, Harris R, et al.: Potential uses of absorbable fibrin adhesive bandage for genitourinary trauma. World J Surg 2001, 25: 1573-1577.
121. Holcomb J, MacPhee M, Hetz S, et al.: Efficacy of a dry fibrin sealant dressing for hemorrhage control after ballistic injury. Arch Surg 1998, 133: 32-35.
122. Holcomb JB, Pusateri AE, Harris RA, et al.: Dry fibrin sealant dressings reduce blood loss, resuscitation volume, and improve survival in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 1999, 47: 233-240; discussion 240-232.